A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for…
By A. Burnett, D. Milligan, A. Prentice, A. Goldstone, M. McMullin, R. Hills, K. Wheatley. Cancer, 2007
609 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/2a83cd0677345689f007f546d8091904762fa052
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. (2010, result): “median survival time of only 4 months and a 2-year OS rate of less than 10%.(45) Similar results have been reported in other series of elderly patients with AML treated with LDAC, with a median OS of 11 months(17,46,47) and a 2-year OS rate of 15%.”
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (2015, methodology): “Those patients considered ineligible for IC because of advanced age or poor performance status are commonly treated with LDAC or BSC alone, which are associated with a median OS of only 5 and 2 months, respectively.(3,4,12)”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, background): “LDAC is generally well-tolerated and produces CR rates in the order of 15% to 25%; however, OS (median, 5-6 months) is unsatisfactory.(212) Therapywith HMAhas been evaluated in randomized trials.”
- Therapeutic advances in acute myeloid leukemia. (2011, neutral): “Such patients have been managed with best supportive care; however, this has been shown in a randomized trial to be inferior to low-dose cytarabine.(74) In these patients alternatives such as hypomethyaltion agents are widely used, but there is so far no randomized data to show that they are superio”